Natera, Inc. $NTRA Shares Bought by New England Research & Management Inc.

New England Research & Management Inc. grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 301.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 6,225 shares of the medical research company’s stock after acquiring an additional 4,675 shares during the quarter. New England Research & Management Inc.’s holdings in Natera were worth $1,002,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Park Avenue Securities LLC acquired a new position in shares of Natera in the second quarter valued at approximately $1,525,000. Baird Financial Group Inc. grew its position in Natera by 277.8% in the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock valued at $4,498,000 after buying an additional 19,576 shares during the last quarter. Atria Investments Inc increased its stake in Natera by 30.1% in the 2nd quarter. Atria Investments Inc now owns 13,242 shares of the medical research company’s stock valued at $2,237,000 after buying an additional 3,063 shares during the period. Zweig DiMenna Associates LLC raised its position in Natera by 3.0% during the 2nd quarter. Zweig DiMenna Associates LLC now owns 124,100 shares of the medical research company’s stock worth $20,965,000 after buying an additional 3,610 shares during the last quarter. Finally, Comerica Bank lifted its stake in shares of Natera by 24.1% in the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock worth $19,954,000 after acquiring an additional 27,379 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insiders Place Their Bets

In related news, Director Rowan E. Chapman sold 4,366 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $243.10, for a total value of $1,061,374.60. Following the sale, the director directly owned 5,777 shares in the company, valued at $1,404,388.70. The trade was a 43.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $238.15, for a total transaction of $714,450.00. Following the transaction, the insider owned 109,061 shares of the company’s stock, valued at $25,972,877.15. This trade represents a 2.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 312,053 shares of company stock worth $64,527,735. 5.63% of the stock is owned by company insiders.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $228.40 on Tuesday. The firm has a market capitalization of $31.59 billion, a price-to-earnings ratio of -99.74 and a beta of 1.63. The business’s 50 day simple moving average is $207.87 and its 200-day simple moving average is $177.24. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $246.90.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.26) earnings per share. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday. Evercore ISI boosted their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. raised their price target on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday. Morgan Stanley lifted their price target on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Finally, BTIG Research increased their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Fifteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $229.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.